Showing 1 - 3 results of 3 for search 'Peter Trask', query time: 0.02s Refine Results
  1. 1
    What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?

    What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials? by Rachael Lawrance, Evgeny Degtyarev, Philip Griffiths, Peter Trask, Helen Lau, Denise D’Alessio, Ingolf Griebsch, Gudrun Wallenstein, Kim Cocks, Kaspar Rufibach

    Published 2020-08-01
    Get full text
    Article
  2. 2
    Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis

    Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis by Miguel A. Canales, Thomas A. Buchholz, Jaisson A.P. Bortolini, Laura M. Fogliatto, Takayuki Ishikawa, Koji Izutsu, Antonio Salar, Jeff P. Sharman, Dirk Klingbiel, Sunny Pokala, Ekaterina Vorozheikina, Peter Trask, Joana Parreira, Kai Hübel

    Published 2023-04-01
    Get full text
    Article
  3. 3
    Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3

    Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3 by Michael U. Callaghan, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse‐Jarres, Víctor Jiménez‐Yuste, Midori Shima, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Flora Peyvandi

    Published 2022-08-01
    Get full text
    Article

Search Tools: